tiprankstipranks
Trending News
More News >
Relmada Therapeutics (RLMD)
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Statistics & Valuation Metrics

Compare
337 Followers

Total Valuation

Relmada Therapeutics has a market cap or net worth of $21.41M. The enterprise value is -$29.22M.
Market Cap$21.41M
Enterprise Value-$29.22M

Share Statistics

Relmada Therapeutics has 33,191,624 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,191,624
Owned by Insiders2.18%
Owned by Institutions5.46%

Financial Efficiency

Relmada Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is ―.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee0.00
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Relmada Therapeutics is 0.00. Relmada Therapeutics’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio
PB Ratio0.44
Price to Fair Value0.44
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00

Income Statement

In the last 12 months, Relmada Therapeutics had revenue of 0.00 and earned 0.00 in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income0.00
Net Income0.00
EBITDA0.00
Earnings Per Share (EPS)0.00

Cash Flow

In the last 12 months, operating cash flow was -53.21M and capital expenditures 0.00, giving a free cash flow of -53.21M billion.
Operating Cash Flow-53.21M
Free Cash Flow-53.21M
Free Cash Flow per Share-1.60

Dividends & Yields

Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.55
52-Week Price Change-81.87%
50-Day Moving Average0.31
200-Day Moving Average1.85
Relative Strength Index (RSI)73.84
Average Volume (3m)2.17M

Important Dates

Relmada Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date

Financial Position

Relmada Therapeutics as a current ratio of 4.45, with Debt / Equity ratio of 0.00%
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Relmada Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Relmada Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00

Balance Sheet

Relmada Therapeutics has $54.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$54.12M billion.
Cash & Marketable Securities$54.12M
Total Debt$0.00
Net Cash-$54.12M
Net Cash Per Share-$1.63
Tangible Book Value Per Share$1.18

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Relmada Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside56.25% Upside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast19.21%

Scores

Smart ScoreN/A
AI Score46.67
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis